Welcome to our dedicated page for Evotec Se SEC filings (Ticker: EVOTF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Evotec Se's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Evotec Se's regulatory disclosures and financial reporting.
Evotec SE received an activist disclosure from MAK Capital, which reported beneficial ownership of 12,503,512 ordinary shares, or about 7.0% of Evotec’s outstanding shares as of March 30, 2026. MAK Fund acquired these shares in open-market purchases for approximately 72,334,719 euros, funded with working capital.
MAK has begun actively engaging Evotec’s leadership. It spoke with the Chairwoman of the Supervisory Board to advocate for strategic and governance changes aimed at enhancing long-term shareholder value. MAK asked Evotec to consider nominating Dr. Wolfgang Hofmann to the Supervisory Board and to pursue an IPO followed by a spin-out of the Just-Evotec Biologics US subsidiary. No agreements have been reached, but MAK intends to continue its engagement.
Evotec launched “Horizon”, the next phase of its multi‑year transformation, introducing a new operating model across operations, science and commercial execution. The company plans to streamline its global footprint to 10 sites and adjust its workforce by up to 800 positions over the next two years.
Structural Horizon measures are expected to deliver approximately €75 million run‑rate cost savings by the end of 2027, against total cash restructuring charges of about €100 million over 2026–2028, plus non‑cash impairments. Evotec enters 2026 with around €60 million annualized cost savings already realized in 2025.
Preliminary unaudited 2025 figures indicate group revenues of about €788 million and adjusted Group EBITDA of roughly €41 million, within prior guidance. For 2026, Evotec guides to group revenues of approximately €700–780 million and adjusted Group EBITDA of about €0–40 million.
The Just – Evotec Biologics segment is expected to post around €259 million revenues, up 40% year on year, and about €53 million adjusted EBITDA, while the Discovery & Preclinical Development segment is expected at roughly €529 million revenues, down 13%, with adjusted EBITDA of about -€12 million.
For 2026–2030, Evotec’s framework targets group revenues above €1 billion (8–12% CAGR) and an adjusted EBITDA margin reaching 20% by 2028 and exceeding that level by 2030.
Novo Holdings A/S now reports no ownership in Evotec SE. In this amended Schedule 13G/A, the Danish investment firm states it beneficially owns 0 ordinary shares of Evotec SE, representing 0.0% of the class, as of 12/31/2025.
The filing shows Novo Holdings has no sole or shared voting power and no sole or shared dispositive power over any Evotec shares. It confirms that Novo Holdings’ holdings are now 5 percent or less of the class, meaning it is no longer a significant beneficial owner under U.S. disclosure rules.